Novel polypeptide and dna thereof

A polypeptide or the salt as claimed in 1, comprising an amino acid sequence consisting of #-30 (Met) to #655 (Arg) of the SEQ ID NO:

• 2.

A polypeptide or the salt comprising an amino acid sequence consisting of #1 (Cys) to #597 (Arg) of the SEQ ID NO:

• 4.

A polypeptide or the salt comprising an amino acid sequence consisting of #-30 (Met) to #597 (Arg) of the SEQ ID NO:

• 4.

A polypeptide or salt, which comprises an amino acid sequence having at least one mutation selected from deletion, displacement and insertion of one or more amino acids in the amino acid sequence as claimed in any one of 1 to 4 and which is a cancer marker or has a BMP binding activity.

A polypeptide as claimed in any one of 1 to 5, which is used as a cancer marker, a bone diseases marker, a cancer remedy or a remedy for bone diseases.

A polynucleotide comprising a nucleotide sequence encoding the polypeptide, claimed in any one of 1 to 6.

A polynucleotide, as claimed in 7, comprising the nucleotide sequence consisting of #91 (T) to #2055 (G) of the SEQ ID NO:

• 1.

A polynucleotide, as claimed in 7, comprising the nucleotide sequence consisting of #1 (A) to #2055 (G) of the SEQ ID NO:

• 1.

A polynucleotide, as claimed in 7, comprising the nucleotide sequence consisting of #91 (T) to #1881 (G) of the SEQ ID NO:

• 3.

A polynucleotide, as claimed in 7, comprising the nucleotide sequence consisting of #1 (A) to #1881 (G) of the SEQ ID NO:

• 3.

A polynucleotide hybridizing with a polynucleotide as claimed in any one of 7 to 11 under a stringent condition and encoding a polypeptide which is a cancer marker or has a BMP-binding activity.

A polynucleotide comprising a complementary nucleotide sequence to a polynucleotide as claimed in any one of 7 to 12.

A polynucleotide as claimed in any one of 7 to 11 or 13, which is used as a cancer marker, a bone diseases marker, a cancer remedy or a remedy for bone diseases.

A polynucleotide selected from the group consisting of oligonucleotide having a sequence identical to that of continuous 5 to 60 bases in the nucleotide sequence as described in the SEQ ID NO:

• 1 or 3, a complementary sequence to the oligonucleotide and their oligonucleotide derivatives.

A recombinant vector comprising the polynucleotide, as claimed in any one of 7 to 13.

A transformer, which is transformed by the recombinant vector as claimed in 16.

A method of preparation of the polypeptide or the salt, including the process of culturing the transformer as claimed in 17 and a recovery process of the produced polypeptide as claimed in any one of 1 to 5 from the culture.

An antibody which specifically recognizes the polypeptide as claimed in any one of 1 to 5.

A method of detection or of a quantitative analysis of polypeptide as claimed in any one of 1 to 5 by using the antibody as claimed in (19) and including following processes

• (a) a process wherein the polypeptide contacts with the antibody,
• (b) a process detecting the bind between the polypeptide and the antibody.

A method of detection of a cancer or a bone disease correlating with the polypeptide as claimed in any one of 1 to 5, which comprises using the antibody as claimed in 19.

A kit for diagnosis of cancer or bone diseases, including the antibody as claimed in 19.

A method of detection or of a quantitative analysis of the mRNA of the polypeptide as claimed in any one of 1 to 5, which comprises using the polynucleotide as claimed in any one of 7 to 13 or 15 and including following processes

• (a) a process of contacting a mRNA with the polypeptide,
• (b) a process of detecting the binding between the mRNA and the polypeptide.

A method of detection of cancer or bone diseases relating to the polypeptide as claimed in any one of 1 to 5 using the method as claimed in 23.

A method for measuring the quantity of the expression of gene encoding the polypeptide as claimed in any one of 1 to 5, using the method as claimed in 23.

A method for inhibiting the transcription of DNA or the translation of mRNA encoding a polypeptide as claimed in any one of 1 to 5, which comprises using the polynucleotide as claimed in any one of 7 to 13 or 15.

A kit for diagnosis of cancer or bone diseases, comprising the polynucleotide as claimed in any one of 7 to 13 or 15.

A method for screening a binding agent to the polypeptide as claimed in any one of 1 to 5, comprising the following processes,

• (a) a process of contacting a test agent with the polypeptide as claimed in any one of 1 to 5,
• (b) a process detecting the binding between a test agent and the polypeptide.

A kit for screening of a binding agent with the polypeptide, comprising the polypeptide as claimed in any one of 1 to 5.

A binding agent which is obtained by using the method for the screening of a binding agent as claimed in 28.

A binding agent as claimed in 30 which is BMP-2 and BMP-4.

A method for screening of a modulating agent of a binding activity between a binding agent as claimed in any one of 30 or 31 and a polypeptide as claimed in any one of 1 to 5, comprising following processes,

• (a) A process, wherein the polypeptide as claimed in any one of 1 to 5 contacts with the binding agent as claimed in any one of 30 and 31 under existence or nonexistence of the test agent,
• (b) A process of comparing both of the binding activities of the polypeptide with the binding agent in the presence and absence of the test agent.

A kit for screening a modulating agent of a binding activity, comprising the polypeptide as claimed in any one of 1 to 5 and the binding agent as claimed in any one of 30 and 31.

A modulating agent of a binding activity which is obtained using the screening method as claimed in 32.

A screening method for a modulating agent of expression of the polypeptide as claimed in any one of 1 to 5 and comprising following processes,

• (a) a process, wherein the cell which expresses the polypeptide as claimed in any one of 1 to 5 contacts with the test agent,
• (b) a process, wherein the change of expression of the polypeptide is detected using the method as claimed in any one of 20 or 23.

A kit for screening a modulating agent of expression of the polypeptide as claimed in any one of 1 to 5 using the method as claimed in 35.

A modulating agent of expression of the polypeptide, which is obtained using the screening method as claimed in 35.

A non-human knock out animal, wherein the DNA encoding the polypeptide as claimed in any one of 1 to 5 is deficient or transformed.

A non-human transgenic animal, wherein the DNA encoding the polypeptide as claimed in any one of 1 to 5 is deficient or transformed.

A pharmaceutical composition containing the antibody as described in (19), the binding agent as claimed in 39, the modulating agent of a binding activity as described in (34) or the modulating agent of expression as claimed in 37.